An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home

Xiao-Juan Lyu, Adrian David Kan, Poh-Heng Chong, Keegan Lin, Yung-Hua Koh, Zhi-Zheng Yeo, Xiao-Juan Lyu, Adrian David Kan, Poh-Heng Chong, Keegan Lin, Yung-Hua Koh, Zhi-Zheng Yeo

Abstract

Background: The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life. When not identified early and effectively managed, delirium symptoms could lead to caregiver and patient distress and harm.

Methods: Eighty patients with a prognosis of 7 days or less will be recruited for an open-label randomised control trial. The two arms compare oral-transmucosal haloperidol 2.5 mg vs olanzapine 5 mg over 72 h. The severity of agitation, delirium and toxicities of treatments will be compared at the 24th, 48th and 72nd hour after drug administration.

Discussion: This trial is the first to compare anti-psychotics in the management of delirium at the dying stage in the home hospice setting using the oral transmucosal route. Ethical considerations, as well as recruitment procedures, are discussed.

Trial registration: This study was registered in ClinicalTrials.gov - identifier NCT04750395.

Keywords: End of life; Haloperidol; Home hospice; Olanzapine; Palliative care; Terminal delirium.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart of clinical trial procedures

References

    1. Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Intern Med. 2001;135(1):32–40. doi: 10.7326/0003-4819-135-1-200107030-00011.
    1. Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y. Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics. 2004;45(2):107–113. doi: 10.1176/appi.psy.45.2.107.
    1. Finucane AM, Jones L, Leurent B, Sampson EL, Stone P, Tookman A, et al. Drug therapy for delirium in terminally ill adults. Cochrane Database Syst Rev. 2020;(1):CD004770. 10.1002/14651858.CD004770.pub3. Accessed 06 Apr 2022.
    1. Hui D, Dev R, Bruera E. Neuroleptics in the management of delirium in patients with advanced cancer. Curr Opin Support Palliat Care. 2016;10(4):316–323. doi: 10.1097/SPC.0000000000000236.
    1. Bush SH, Leonard MM, Agar M, Spiller JA, Hosie A, Wright DK, Meagher DJ, Currow DC, Bruera E, Lawlor PG. End-of-life delirium: issues regarding recognition, optimal management, and the role of sedation in the dying phase. J Pain Symptom Manage. 2014;48(2):215–230. doi: 10.1016/j.jpainsymman.2014.05.009.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington DC: American psychiatric association; 2013.
    1. Singapore Statutes Online. Mental Capacity Act (Chapter 177A). Singapore: Attorney-General’s Chambers of Singapore; 2010. . Accessed 6 Apr 2022.
    1. Agar M, Ko DN, Sheehan C, Chapman M, Currow DC. Informed consent in palliative care clinical trials: challenging but possible. J Palliat Med. 2013;16(5):485–491. doi: 10.1089/jpm.2012.0422.
    1. Ministry of Health. Human Biomedical Research Act 2015. . Accessed 6 Apr 2022.
    1. Jain R, Arun P, Sidana A, Sachdev A. Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium. Indian J Psychiatry. 2017;59(4):451–456. doi: 10.4103/psychiatry.IndianJPsychiatry_59_17.
    1. Lin CJ, Sun FJ, Fang CK, Chen HW, Lai YL. An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. J Internal Med Taiwan. 2008;19(4):346–354.
    1. Fargason RE, Birur B. Switching antipsychotics: A guide to dose equivalents. Curr Psychiatr. 2021;20(4):13–14.
    1. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symp Manage. 1997;13(3):128–137. doi: 10.1016/S0885-3924(96)00316-8.
    1. Lawlor PG, Nekolaichuk C, Gagnon B, Mancini IL, Pereira JL, Bruera ED. Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: Assessing delirium in advanced cancer. Cancer. 2000;88(12):2859–67. 10.1002/1097-0142(20000615)88:12<2859::AID-CNCR29>;2-T.
    1. Bush SH, Grassau PA, Yarmo MN, Zhang T, Zinkie SJ, Pereira JL. The Richmond Agitation-Sedation Scale modified for palliative care inpatients (RASS-PAL): a pilot study exploring validity and feasibility in clinical practice. BMC Palliative Care. 2014;13(1):17. doi: 10.1186/1472-684X-13-17.
    1. Hui D, Hess K, Dibaj SS, Arthur J, Dev R, Dalal S, Reddy S, Bruera E. The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer. 2018;124(10):2246–2252. doi: 10.1002/cncr.31312.
    1. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. NIH publication 09-7473. 2009. Revised June14, 2010. . Accessed 6 Apr 2022.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit